Merck KGaA's ATR cancer drug cleared for further trials afte...

Merck KGaA’s ATR inhibitor cancer drug has been cleared for further clinical trials after it showed encouraging activity in a phase 1 study. 

Merck & Co's Keytruda outperforms chemo in MSI-High colorect...

Merck & Co’s Keytruda (pembrolizumab) immunotherapy has outperformed standard of care in untreated colorectal cancer with certain mutations, offering patients a single-agent therapy opt

FDA approves Pfizer/Merck KGaA combo in advanced colorectal ...

The FDA has approved a combination of Pfizer’s Braftovi and Merck KGaA’s Erbitux for a form of untreated metastatic colorectal cancer, the first targeted drug regimen for this form of the d

BI opens second branch of digital lab in China

Boehringer Ingelheim has announced that it will open a second branch of its digital lab, BI X, in July this year in China.

The many faces of patient-pharma co-creation

Ahead of her appearance at eyeforpharma Barcelona, Merck’s director of patient advocacy and strategic partnerships, Vanessa Pott, tells us how the company is approaching patient centric

Merck, Pfizer’s Bavencio flunks head and neck cancer trial